It is very uncertain whether summary of findings: Comparison 1 ‐ deferiprone (DFP) changes total reported SAEs (from therapy, disease, non‐adherence) compared with deferoxamine (DFO) (very low certainty).
It is very uncertain whether summary of findings: Comparison 4 ‐ deferasirox (DFX) film‐coated… changes incidence of SAEs compared with DFX dispersible tablets (very low certainty).
The review found no eligible studies for this question.
Summary of findings: Comparison 5 ‐ deferiprone (DFP) plus… showed no clear difference in incidence of SAEs compared with DFP (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether summary of findings: Comparison 1 ‐ deferiprone (DFP) changes all‐cause mortality compared with deferoxamine (DFO) (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Summary of findings: Comparison 7 ‐ deferiprone (DFP) plus… may leads to lower adherence to iron chelation therapy rates (n, N) compared with DFP plus deferasirox (DFX) (low certainty).
It is very uncertain whether summary of findings: Comparison 7 ‐ deferiprone (DFP) plus… changes all‐cause mortality ‐ at 1 year ‐ trial end compared with DFP plus deferasirox (DFX) (very low certainty).